Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Ibuprofen (Primary) ; Sodium cromoglicate (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms COGNITE
- Sponsors AZTherapies
- 04 Nov 2019 According to an AZTherapies media release, Parid Sava, Ph.D., will be presenting data from this trial at BIO-EUROPE 25th Annual International Partnering Conference, taking place from November 11 to 13, 2019 in Hamburg, Germany.
- 17 Oct 2019 According to an AZTherapies media release, proceeds from the financing round (as of 17th Oct 2019) are expected to fund the completion of this trial by the end of next year.
- 23 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2020.